Shannon Patrick

Shannon Patrick is a patent litigation attorney at Finnegan, Henderson, Farabow, Garrett & Dunner, specializing in disputes within the life sciences, particularly those involving Abbreviated New Drug Applications (ANDA) and biologics. Her technical acumen spans chemical and biologic fields, including recombinant adeno-associated virus (AAV) vectors, small molecule Cyclin dependent kinases (CDK) and Janus kinase (JAK) inhibitors, and mechanical technologies like aluminum alloys.

Ms. Patrick primarily represents innovator pharmaceutical and biotechnology companies, working to defend their intellectual property. Her tracked appearance shows her acting on the defendant side in the case of Genzyme Corporation v. Novartis Gene Therapies, Inc., where she successfully defended Novartis. Her practice involves safeguarding clients' patents against infringement actions and generic challenges.

A significant achievement in her career includes successfully defending Novartis against Genzyme Corporation's multiple patent infringement actions and Inter Partes Review (IPR) proceedings concerning recombinant adeno-associated virus vector technology for the gene therapy Zolgensma®. This matter settled favorably for Novartis after several patents were invalidated during claim construction, others found not literally infringed, and multiple IPRs were instituted. She was also trial counsel for Novartis in an ANDA litigation against multiple generics related to KISQALI®, a breast cancer treatment, which resulted in a favorable settlement.

Shannon Patrick also has substantial experience with proceedings before the Patent Trial and Appeal Board (PTAB), where she assists clients in preparing petitions for IPRs and navigates other post-grant review processes. She is admitted to the State Bar of Georgia and is a graduate of Emory University School of Law.